Repairing defect and preventing collapse of femoral head in a steroid-induced osteonecrotic of femoral head animal model using strontium-doped calcium polyphosphate combined BM-MNCs

Journal of Materials Science: Materials in Medicine

Volumn 26, Issue 2, 2015, Pages 1-9

  Kang, Pengde ^a   Xie, Xiaowei ^a   Tan, Zhen ^a   Yang, Jing ^a   Shen, Bin ^a   Zhou, Zongke ^a   Pei, Fuxing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CARTILAGE; DEFECTS; REPAIR; STRONTIUM COMPOUNDS;

ACETATE INJECTION; ARTICULAR CARTILAGES; CALCIUM POLYPHOSPHATE; JOINT SPACE NARROWING; MECHANICAL WEAKENING; MONONUCLEAR CELLS; OSTEONECROSIS OF THE FEMORAL HEADS (ONFH); TRABECULAR BONES;

CALCIUM COMPOUNDS;

CALCIUM POLYPHOSPHATE; METHYLPREDNISOLONE ACETATE; POLYPHOSPHATE; STRONTIUM; UNCLASSIFIED DRUG; VASCULOTROPIN; BONE PROSTHESIS; CALCIUM PHOSPHATE; DRUG IMPLANT; METHYLPREDNISOLONE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; BONE DEVELOPMENT; BONE GRAFT; BONE MARROW DERIVED MONONUCLEAR CELL; BONE REMODELING; COLLAPSE; CONTROLLED STUDY; FEMUR HEAD NECROSIS; HISTOPATHOLOGY; IMPLANTATION; JOINT CAVITY; MALE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; TRABECULAR BONE; ADMINISTRATION AND DOSAGE; ANIMAL; BONE PROSTHESIS; CHEMICALLY INDUCED; CHEMISTRY; DEVICE FAILURE ANALYSIS; DRUG IMPLANT; IMMUNOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSTHESIS; THERAPEUTIC USE; TISSUE SCAFFOLD; TREATMENT OUTCOME;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; BONE SUBSTITUTES; CALCIUM PHOSPHATES; COMBINED MODALITY THERAPY; DRUG IMPLANTS; EQUIPMENT FAILURE ANALYSIS; FEMUR HEAD NECROSIS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; METHYLPREDNISOLONE; PROSTHESIS DESIGN; RABBITS; STRONTIUM; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84922239680     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-015-5402-x     Document Type: Article

References (49)

1. Marker DR, Seyler TM, McGrath MS, Delanois R, Ulrich SD, Mont MA. Treatment of early stage osteonecrosis of the femoral head. J Bone Joint Surg Am. 2008;90(suppl4):175–87.
2. McGrory BJ, York SC, Iorio R, Macaulay W, Pelker RR, et al. Current practices of AAHKS members in the treatment of adult osteonecrosis of the femoral head. J Bone Joint Surg Am. 2007;89:1194–204.
3. Lieberman JR, Berry DJ, Mont MA, Aaron RK, Callaghan JJ, Rajadhyaksha AD, Urbaniak JR. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect. 2003;52:337–55.
4. Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE. The natural history of untreated asymptomatic osteonecrosis of the femoral head: A systematic literature review. J Bone Joint Surg Am. 2010;92:2165–70.
5. Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. Bone Joint Surg Am. 2006;88:1117–32.
6. Kang P, Shen B, Yang J, Cheng J, Pei F. Repairing defect and preventing collapse of canine femoral head using titanium implant enhanced by autogenous bone graft and rhBMP-2. Connect Tissue Res. 2007;48:171–9.
7. Cui Q, Botchwey EA. Emerging ideas: treatment of precollapse osteonecrosis using stem cells and growth factors. Clin Orthop Relat Res. 2011;469:2665–9.
8. Tang TT, Lu B, Yue B, Xie XH, Xie YZ, Dai KR, et al. Treatment of osteonecrosis of the femoral head with hBMP-2-gene-modified tissue-engineered bone in goats. J Bone Joint Surg Br. 2007;89:127–9.
9. Marciniak D, Furey C, Shaffer JW. Mechanical consequences of core drilling and bone-grafting on osteonecrosis of the femoral head. J Bone Joint Surg Am. 1993;75:1358–67.
10. Chen CC, Lin CL, Chen WC, Shih HN, Ueng SWN, Lee MS. Vascularized iliac bone-grafting for osteonecrosis with segmental collapse of the femoral head. J Bone Joint Surg Am. 2009;91:2390–4.
11. Gu Z, Zhang X, Li L, Wang Q, Yu X, Feng T. Acceleration of segmental bone regeneration in a rabbit model by strontium-doped calcium polyphosphate scaffold through stimulating VEGF and bFGF secretion from osteoblasts. Mater Sci Eng, C. 2013;33:274–81.
12. Li Y, Li J, Zhu S, Luo E, Feng G, Chen Q, et al. Effects of strontium on proliferation and differentiation of rat bone marrow mesenchymal stem cells. Biochem Biophys Res Commun. 2012;418:725–30.
13. Che YW, Feng T, Shi GQ, Ding YL, Yu XX, Zhang XH, et al. Interaction of endothelial cells with biodegradable strontium-doped calcium polyphosphate for bone tissue engineering. Appl Surf Sci. 2008;255:331–5.
14. Tat SK, Pelletier JP, Mineau F, Caron Jh, Martel-Pelletier J. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone. 2011;49:559–67.
15. Li Z, Lu WW, Chiu PKY, Lam RWM, Xu B, Chung KMC, et al. Strontium-calcium coadministration stimulates bone matrix osteogenic factor expression and new bone formation in a large animal model. J Orthop Res. 2009;27:758–62.
16. Barbara A, Delannoy P, Denis BG, Marie PJ. Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells. Metabolism. 2004;53:532–7.
17. Choudhary S, Halbout P, Alander C, Raisz L, Pilbeam C. Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: involvement of prostaglandins. J Bone Miner Res. 2007;22:1002–10.
18. Takahashi N, Sasaki T, Tsouderos Y, Suda T. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res. 2003;18:1082–7.
19. Baron R, Tsouders Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol. 2002;450:11–7.
20. Henrotin Y, Labasse A, Zheng SX, Galais P, Tsouderos Y, Crielaard JM, et al. Strontium ranelate increases cartilage matrix formation. J Bone Miner Res. 2001;16:299–308.
21. Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of formation and resorption in vitro. Bone. 2008;42:129–38.
22. Gu Z, Xie H, Li L, Zhang X, Liu F, Yu X. Application of strontium-doped calcium polyphosphate scaffold on angiogenesis for bone tissue engineering. J Mater Sci Mater Med. 2013;24(5):1251–60.
23. Chen YW, Shi GQ, Ding YL, Yu XX, Zhang XH, Zhao CS, Wan CX. In vitro study on the influence of strontium-doped calcium polyphosphate on the angiogenesis-related behaviors of HUVECS. J Mater Sci Mater Med. 2008;19:2655–62.
24. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002;405:14–23.
25. Gangji V, Maertelaer VD, Hauzeur JP. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone. 2011;49:1005–9.
26. Zhao D, Cui D, Wang B, Tian F, Guo L, Yang L, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012;50:325–30.
27. Gangji V, Hauzeur JP. Treating osteonecrosis with autologous bone marrow cells. Skeletal Radiol. 2010;39:209–11.
28. Qiu K, Zhao XJ, Wan CX, Zhao CS, Chen YW. Effect of strontium ions on the growth of ROS17/2.8 cells on porous calcium polyphosphate scaffolds. Biomaterials. 2006;27:1277–86.
29. Miyanishi K, Yamamoto T, Irisa T, Yamashita A, Jingushi S, Noguchi Y, et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone. 2002;30:185–90.
30. Kang PD, Pei FX, Shen B, Yang J, Zhou ZK, Cheng JQ. Lovastatin inhibits adipogenesis and prevents osteonecrosis in steroid-treated rabbits. Joint Bone Spine. 2008;75:696–701.
31. Kang P, Gao H, Pei F, Shen B, Yang J, Zhou Z. Effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits. Int J Exp Pathol. 2010;91:235–43.
32. Mont MA, Jones LC, Elias JJ, Inoue N, Yoon TR, Chao EYS, et al. Strut-autografting with and without osteogentic protein-1: a preliminary study of a canine femoral head defect model. J Bone Join Surg Am. 2001;83:1013–22.
33. Simkin PA, Downey DJ. Hypothesis: retrograde embolization of marrow fat may cause osteonecrosis. J Rheumatol. 1987;14:870–2.
34. Gangji V, Hauzeur JP, Schoutens A, Hinsenkamp M, Appelboom T, Egrise D. Abnormalities in the replicative capacity of osteoblastic cells in the proximal femur of patients with osteonecrosis of the femoral head. J Rheumatol. 2003;30:348–51.
35. Hernigou P, Beaujean F. Abnormalities in the bone marrow of the iliac crest in patients who have osteonecrosis secondary to corticosteroid therapy or alcohol abuse. J Bone Joint Surg Am. 1997;79:1047–53.
36. Calder JD, Pearse MF, Revell PA. The extent of osteocyte death in the proximal femur of patients with osteonecrosis of the femoral head. J Bone Joint Surg Br. 2001;83:419–22.
37. Ko JY, Wang FS, Wang CJ, Wong T, Chou WY, Tseng SL. Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone. 2010;46:584–91.
38. Gangji V, Hauzeur JP, Matos C, De MV, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am. 2004;86:1153–60.
39. Zhang WB, Shen YH, Pan HB, Lin KL, Liu XG, Darvell BW, et al. Effects of strontium in modified biomaterials. Acta Biomater. 2011;7:800–8.
40. Capuccini C, Torricelli P, Sima F, Boanini E, Ristoscu C, Bracci B, et al. Strontium-substituted hydroxyapatite coatings synthesized by pulsed-laser deposition: in vitro osteoblast and osteoclast response. Acta Biomater. 2008;4:1885–93.
41. Braux J, Velard F, Guillaume C, Bouthors S, Jallot E, Nedelec JM, et al. A new insight into the dissociating effect of strontium on bone resorption and formation. Acta Biomater. 2011;7:2593–603.
42. Ni GX, Yao ZP, Huang GT, Liu WG, Lu WW. The effect of strontium incorporation in hydroxyapatite on osteoblasts in vitro. J Mater Sci Mater Med. 2011;22:961–7.
43. Gentleman E, Fredholm YC, Jell G, Lotfibakhshaiesh N, O’Donnell MD, Hill RG, et al. The effects of strontium-substituted bioactive glasses on osteoblasts and osteoclasts in vitro. Biomaterials. 2010;31:3949–56.
44. Atkins GJ, Welldon KJ, Findlay DM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int. 2009;20:653–64.
45. Nia GX, Lua WW, Xu B, Chiu KY, Yang C, Lia ZY, et al. Interfacial behaviour of strontium-containing hydroxyapatite cement with cancellous and cortical bone. Biomaterials. 2006;27:5127–33.
46. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007;117:1616–26.
47. Marie PJ. Strontium renelate: a new insight into its dual model of action. Bone. 2007;40:5–8.
48. Karsenty G. The complexities of skeletal biology. Nature. 2003;423:316–8.
49. Zhu LL, Zaidi S, Peng Y, Zhou H, Moonga BS, Blesius A, et al. Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophy Res Commun. 2007;355:307–11.